ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.21, Zacks reports.
ENDRA Life Sciences Price Performance
Shares of NASDAQ:NDRA remained flat at $4.47 during trading on Friday. 51,812 shares of the stock were exchanged, compared to its average volume of 60,848. The business’s 50-day simple moving average is $4.85 and its two-hundred day simple moving average is $4.60. ENDRA Life Sciences has a fifty-two week low of $2.96 and a fifty-two week high of $9.85. The company has a market capitalization of $5.68 million, a price-to-earnings ratio of -0.55 and a beta of -0.05.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on NDRA. Weiss Ratings raised ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Ascendiant Capital Markets decreased their price target on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $25.00.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.
ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.
Featured Stories
- Five stocks we like better than ENDRA Life Sciences
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
